STOCK TITAN

Brainstorm Cell Therapeutics, Inc. - BCLI STOCK NEWS

Welcome to our dedicated news page for Brainstorm Cell Therapeutics (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Brainstorm Cell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Brainstorm Cell Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
-
Rhea-AI Summary
BrainStorm Cell Therapeutics announces securities purchase agreement for registered direct offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
Rhea-AI Summary
BrainStorm Cell Therapeutics Inc. appoints Dr. Bob Dagher as Executive Vice President and Chief Development Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.12%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
conferences
-
Rhea-AI Summary
BrainStorm Cell Therapeutics Inc. announces that the U.S. FDA will convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (ADCOM) to review the Biologics License Application (BLA) for NurOwn®, its stem cell therapy for ALS. The advisory committee meeting is scheduled for September 27, 2023, and the Prescription Drug User Fee Act (PDUFA) action date is targeted for December 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Brainstorm Cell Therapeutics, Inc.

Nasdaq:BCLI

BCLI Rankings

BCLI Stock Data

36.02M
61.21M
12.8%
5.99%
1.97%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
New York

About BCLI

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr